PPARA and metabolic dysfunction-associated steatohepatitis: The whole liver weight did not differ between the PBS- and pan PPAR-iMSC-EVs-treated NASH mice (data not shown; MCD + PBS, 5.78 ± 0.12% vs. MCD + pan PPAR-iMSC-EVs, 5.33 ± 0.23%).